





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Larsen, et al.

Serial No.: 09/870,276

Group Art Unit: 3749

Filed: May 30, 2001

Examiner: Nguyen

For: A Disposable Double Point Injection Needle and an Insulin Injection System

Comprising a Disposable Double Point Injection Needle

AMENDMENT NO FEE TRANSMITTAL

Commissioner for Patents Washington, DC 20231

Sir:

RECEIVED

OCT 2 5 2002

TECHNOLOGY CENTER R3700

Transmitted herewith is an Amendment for the above-identified application.

No fee is required for this Amendment. Please charge any additional fee to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Respectfully submitted,

Date: October 15, 2002

Marc A. Began, Reg. No. 48,829

Mun or

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540 (609) 987-5800

23650
PATENT TRADEMARK OFFICE

R



Attorney Docket No.: 6251.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Larsen, et al.

Serial No.: 09/870,276

Group Art Unit: 3749

Filed: May 30, 2001

Examiner: Nguyen

For: A Disposable Double Point Injection Needle and an Insulin Injection System Comprising

a Disposable Double Point Injection Needle

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

RECEIVED

OCT 2 5 2002

TECHNOLOGY CENTER R3700

- Amendment No Fee Transmittal
- 2. Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on October 15, 2002.

Maya Faison-Phillip

(name of person mailing paper)

(signature of person mailing paper)